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Abstract
Introduction
• Over the past decade or so, people have become increasingly 
hesitant to receive many recommended vaccinations. There are 
several causes related to this hesitation; increasing number of 
recommended vaccines, public misconception, and just poor 
understanding of vaccination and/or the diseases these 
vaccines are preventing. 
• There are approximately 120-150 different strains of HPV, some 
more virulent than others.
• The more virulent strains are known to cause genital warts and 
several types of cancer in both men and women later in life. 
• According to the CDC, each year about 42,700 new cases of 
cancer are found in parts of the body where human 
papillomavirus (HPV) is often found. It is estimated that HPV 
causes about 33,700 of these cancers.
Research Questions
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• it is estimated that in the United States alone, 14 million 
persons are infected with HPV annually, and 79 million 
persons have prevalent infection.
• Since the initial release of the first HPV vaccine in 2006, 
the vaccine (Gardasil) has been updated to prevent 9 of 
the more virulent strains of HPV rather than 4 which is 
what the initial vaccine prevented. Another vaccination 
option is the bivalent HPV vaccine (Cervarix) which only 
prevents the high-risk HPV strains 16 and 18, however it 
may be more effective in preventing cancers related to 
these specific HPV strains. 
• According to the CDC, only 49% of adolescents between 
the ages of 13 and 17 were up to date with their HPV 
vaccination schedule. This is well short of the goal of 80% 
vaccination amongst this age group.
• Increasingly alarming to the information above is the fact 
that male vaccination rates are even lower than the 
already low rates in female patients.
• Studies have shown the best seroconversion rates are 
among adolescents between 11 and 16 years of age and 
before first sexual encounter. 
• Men who have sex with other men are much more likely 
to be infected with high-risk HPV. 
• There is very minimal evidence to suggest that HPV 
vaccination can cause any autoimmune diseases such as 
Guillian-Barre syndrome. The majority of the evidence 
shows no increased risk. 
• It is the responsibility of a healthcare provider to provide 
his/her patients with the most up to date, significant 
evidence regarding all vaccinations. 
• Long term side effects as well as prolonged 
seroconversion must be evaluated to truly gauge the 
efficacy, safety, and impact HPV vaccination will truly 
have. 
HPV is the most common sexually transmitted infection in the 
United States, affecting approximately 75-80% of young adults 
at some point in their lives, and it is also known to be directly 
related to several forms of cancer including cervical, vaginal, 
penile, anal, oral, and oropharyngeal cancer. Vaccination against 
several high-risk strains of HPV first became available in the 
U.S. in June of 2006 and has been proven to be effective in 
creating antibodies against several strains of high-risk HPV, 
potentially decreasing and preventing more than 30,000 new 
cases of HPV related cancers each year. Despite this fact, HPV 
vaccination rates remain low. Although vaccination is 
recommended for both female and male adolescents, male 
vaccination rates remain lower than female, likely due to the fact 
that HPV is most commonly associated with cervical cancer. 
However; evidence shows that among certain male populations, 
such as homosexuals, HPV related cancer rates may be as high 
in males as cervical cancer rates in females, demonstrating the 
potential impact of HPV vaccination in males. Lack of 
knowledge, and a perception of a lack of necessity for male 
vaccination are substantial barriers for achieving targeted 
vaccination rates. There is evidence demonstrating that proper 
education, or simply having meaningful conversation with 
patients, can help to increase patient compliance of receipt of 
HPV vaccination. Additionally, there is an abundance of 
unverified information attempting to link HPV vaccination to 
severe adverse reactions. There is minimal evidence to support 
such a correlation, but some studies do suggest it. A need for 
further investigation is warranted. 
• In adolescent male patients, does vaccination against 
human papilloma virus (HPV) significantly decrease 
incidence of several types of cancer later in life, compared 
to adolescent males who have not received an hpv 
vaccine?
• Does vaccination against Human Papilloma Virus cause 
potentially severe adverse reactions, such as autoimmune 
diseases? 
• Can adequately educating patients, or a patient’s 
caregiver, lead to an increase in compliance in receiving 
HPV vaccination in male adolescents? 
• you want to emphasize.
• There are more than 150 known strains of HPV. Only a 
few are virulent, these are spread through sexual contact 
and cause genital warts and can lead to some types of 
cancer (Centers for Disease Control and Prevention, 
2016)
• HPV vaccines were first FDA approved in 2006. In the 
U.S. today there are two HPV vaccines available. They 
have a similar efficacy, but one only covers two strains of 
HPV and the other covers nine strains. (DiMario, 2015)
• in developing countries incidences of cervical cancers are 
far more prevalent than other cancers caused by HPV 
due to lack of routine screening, but in the developed 
world where routine screenings are performed, rates of 
cancers in men related to HPV are estimated to be much 
closer to rates of cervical cancer caused by HPV. 
(Palefsky, 2010) 
• One meta-analysis revealed a prevalence of 49% of any 
type of human papillomavirus and 35% of high-risk 
human papillomavirus in all men within the studies 
reviewed, but men who have sex with other men are more 
likely to be infected with high-risk HPV. (Rodriguez-
Alvarez, 2018)
• One meta-analysis evaluates nearly 500,000 cases and 
identifies no correlation between autoimmune disorders 
and the HPV vaccine. (Genovese, 2018)
• This scholarly project was intended to inform and educate 
parents and clinicians of the importance of HPV 
vaccination in adolescent male patients, distinguish fact 
from fiction regarding adverse reactions caused by HPV 
vaccination, and to identify barriers causing skepticism 
and hesitancy in receiving HPV vaccination. With society’s 
growing concerns regarding vaccinations, it is increasingly 
important to inform patients with the most accurate and up 
to date information about vaccines. 
• With increasing education about HPV and HPV 
vaccination, we can potentially improve these vaccination 
rates and in doing so, decrease rates of HPV related 
cancers. Hopefully the information provided in scholarly 
project will aid clinicians to provide patients and parents 
with the necessary information to make informed decisions 
on whether to vaccinate their children against Human 
Papilloma Virus. 
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Statement of the Problem
• It is well established and accepted that HPV can lead to 
cervical cancer in females later in life. Consequences in 
males who have HPV are not as known or accepted by 
much of the public. Parents of adolescent male patients 
tend to be more hesitant in agreeing to vaccinate their male 
children. 
• Additionally, there are many non-verified reports across 
social media and the internet stating that the HPV vaccine 
may cause different autoimmune diseases such as Gilliam 
Barre Syndrome or other severe conditions such as 
postural orthostatic tachycardia syndrome (POTS)
• It is the responsibility of health care providers to properly 
educate patients and parents of patients whom are 
recommended to receive vaccination against HPV and 
prevent potentially severe complications later in life. 
Unfortunately, this is often not what actually happens
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Number of HPV-Associated Cancer Cases per Year 
 
Cancer site 
Average number of cancers per year in 
sites where HPV is often found (HPV-
associated cancers) 
Percentage probably 
caused by any HPV 
typea 
Number probably 
caused by any HPV 
typea 
Cervix 11,866 91% 10,751 
Vagina 846 75% 635 
Vulva 3,934 69% 2,707 
Penis 1,269 63% 803 
Anusb 6,530 91% 5,957 
Female 4,333 93% 4,008 
Male 2,197 89% 1,949 
Oropharynx 18,226 70% 12,885 
Female 3,412 63% 2,160 
Male 14,814 72% 10,725 
TOTAL 42,671 79% 33,737 
Female 24,391 83% 20,260 
Male 18,280 74% 13,477 
